SHANGHAI, April 12, 2012
SHANGHAI, April 12, 2012 /PRNewswire/ --
Most biopharma executives agree that the current model for innovation is broken. From declining R&D productivity, to demands from payers to show real-world value, to the much publicized patent cliff, the industry faces unprecedented challenges that require fundamental changes across the entire value chain.
To discuss these strategic challenges and potential solutions for renewed growth, Elsevier Business Intelligence and The BayHelix Group invite you to attend the 3rd PharmAsia Summit (http://www.PharmAsiaSummit.com), to be held September 24 - 26, 2012, in Shanghai.
"Our location in Shanghai - the center of China's pharma industry - is no accident," said Jimmy Zhang, Chairman BayHelix. "China, and other major emerging markets, provides a real-world laboratory to experiment with new models of innovation across the entire value chain, nurtured by a climate less encumbered by legacy systems or engrained mindsets."
Indeed, the rise of emerging markets has provided multinationals with significant new growth opportunities and cash flow - but also the challenge to achieve better health outcomes in regions struggling with affordability barriers and huge unmet medical needs.
Given the scope of challenges, there is a sense of urgency and government focus in emerging markets, creating a ripe environment for companies to test new R&D and business models in collaboration with industry peers, governments, payers, academia, contract research organizations, healthcare professionals and other key stakeholders.
"These new models, tested in emerging markets, could also help drive fundamental change in established markets like the U.S. and Europe, creating opportunities to reshape the biopharma industry for the 21st Century," said Gerry Stoia, President of Elsevier Business Intelligence.
At the PharmAsia Summit-Shanghai, Elsevier and BayHelix will feature data and case studies from China, India and other emerging markets focusing on two key imperatives of innovation: (1) Getting Better Products To Market Faster; and (2) Creating Value For Patients And Payers. Summit attendees can also get a firsthand look at innovation in China by opting to tour a local science and technology park as part of a special conference delegation.
To kick off the Summit, Elsevier, BayHelix and the Monitor Group will release an exclusive report exploring how China could disrupt the innovation paradigm, based on an industry survey and discussions with key corporate leaders and policy makers.
The program for this year's Summit has been created by an advisory board chaired by Steve Yang, VP, Head of R&D for Asia & Emerging Markets, AstraZeneca PLC.
For further information, visit: http://www.PharmAsiaSummit.com. To participate in the industry survey (which includes a 15% discount to attend the PharmAsia Summit-Shanghai) visit: http://bit.ly/I109bx.
About Elsevier Business Intelligence
Elsevier Business Intelligence, a global leader in the field of healthcare industry information, provides business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, e-learning, databases and reports, Elsevier Business Intelligence places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis. Our leading publications include PharmAsia News, IN VIVO and "The Pink Sheet." For more information, visit: http://www.ElsevierBi.com.
About BayHelix Group
BayHelix is an organization of leaders of Chinese heritage in the global life sciences and healthcare community. We aspire to shape the growth of the life sciences and healthcare industry around the Pacific Rim and beyond, foster and create business opportunities, supply and nurture the leaders for the community, and network and share information and experience. BayHelix is a non-profit organization and its membership is by-invitation-only. For more information, visit: http://www.bayhelix.org.
About Elsevier Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively. A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Last updated on: 15/04/2012